Antaros Medical, a service provider in drug development using imaging, has made two key appointments, Klas Malmberg, as the Chief Medical Officer and Elisabeth Bolling-Sternevald, as the Chief Operating Officer.
Klas Malmberg MD, PhD, FESC, is an experienced cardiologist, medical expert and senior lecturer with wide experience from both academic and pharmaceutical industry. Klas extensive merit list embraces among others Karolinska Insitute in Sweden, McMaster University Hamilton in Canada, GlaxoSmithKline, F-Hoffman- Roche and AstraZeneca. Over the years, Klas has shared his work through publications in several leading scientific journals, presentations at international meetings and participation in a number of steering committees.
Elisabeth Bolling-Sternevald, PhD (Doctor of medicine) brings in extensive global experience from disease area strategy work, drug portfolio development and global project leadership. Elisabeth was during her career affiliated to both Karolinska Institute and Linköpings University and has published numerous papers in well-known scientific journals. Elisabeth has devoted many years of her career to cardiovascular, metabolic and gastrointestinal (CVMD) drug development at AstraZeneca, where her most recent position was Global TA Head of Clinical Operations CVMD. Elisabeth is also recognised as an engaging leader that motivates and develops people around her.
Both Klas and Elisabeth have been working in various countries in many years. Johannes Hulthe, Antaros Medical CEO commented: “We are very excited about getting Klas and Elisabeth on-board and we very much look forward to benefit from their robust medical and pharmaceutical leadership. We see both appointments as strategic investments which will further strengthen our abilities to empower our clients as evidence-based decision-makers in clinical drug development. “
Source: Antaros medical